Armando Tripodi1, Lidia Padovan2, Chantarangkul Veena2, Erica Scalambrino2, Sophie Testa3, Flora Peyvandi4. 1. Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Department of Clinical Sciences and Community Health, Università degli Studi di Milano, MiIano, ltaly; IRCCS Cà Granda Maggiore Hospital Foundation, Milano, Italy. Electronic address: armando.tripodi@unimi.it. 2. Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Department of Clinical Sciences and Community Health, Università degli Studi di Milano, MiIano, ltaly; IRCCS Cà Granda Maggiore Hospital Foundation, Milano, Italy. 3. Haemostasis Thrombosis Center, General Hospital, Cremona, Italy. 4. Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Department of Clinical Sciences and Community Health, Università degli Studi di Milano, MiIano, ltaly; IRCCS Cà Granda Maggiore Hospital Foundation, Milano, Italy; Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milano, Italy.
Abstract
BACKGROUND AND OBJECTIVES: Apixaban is a direct oral anticoagulant (DOAC) targeting factor Xa and thus quenching thrombin generation and clot formation. However, little information is available on the influence that apixaban may have on the parameters of thrombin generation. METHODS: Aliquots of a pooled normal plasma have been added with increased concentrations of purified apixaban and were used to assess the degree of modification brought about by the drug on the basic tests of coagulation prothrombin and activated partial thromboplastin time (PT and APTT) and on thrombin generation parameters. RESULTS: The study shows that while apixaban has little effect on PT or APTT it does affect all the parameters of thrombin generation, including the lag-time (which is increased), the endogenous thrombin potential (ETP) and thrombin-peak (both decreased although to a different extent), and the velocity index (decreased). Interestingly, the above effects were more pronounced when the measurements were recorded in the presence of thrombomodulin, thus making the ratio (with/without thrombomodulin) to decrease consistently as a function of the apixaban concentrations. CONCLUSIONS: These findings support the antithrombotic properties of apixaban and can help to understand the mechanism(s) of action of this drug. Thrombin generation could be used as a convenient laboratory tool to assess the anticoagulant activity of other drugs and to make between-DOAC comparison.
BACKGROUND AND OBJECTIVES:Apixaban is a direct oral anticoagulant (DOAC) targeting factor Xa and thus quenching thrombin generation and clot formation. However, little information is available on the influence that apixaban may have on the parameters of thrombin generation. METHODS: Aliquots of a pooled normal plasma have been added with increased concentrations of purified apixaban and were used to assess the degree of modification brought about by the drug on the basic tests of coagulation prothrombin and activated partial thromboplastin time (PT and APTT) and on thrombin generation parameters. RESULTS: The study shows that while apixaban has little effect on PT or APTT it does affect all the parameters of thrombin generation, including the lag-time (which is increased), the endogenous thrombin potential (ETP) and thrombin-peak (both decreased although to a different extent), and the velocity index (decreased). Interestingly, the above effects were more pronounced when the measurements were recorded in the presence of thrombomodulin, thus making the ratio (with/without thrombomodulin) to decrease consistently as a function of the apixaban concentrations. CONCLUSIONS: These findings support the antithrombotic properties of apixaban and can help to understand the mechanism(s) of action of this drug. Thrombin generation could be used as a convenient laboratory tool to assess the anticoagulant activity of other drugs and to make between-DOAC comparison.
Authors: Tuukka A Helin; Lauri Virtanen; Mikko Manninen; Jarkko Leskinen; Juhana Leppilahti; Lotta Joutsi-Korhonen; Riitta Lassila Journal: J Thromb Thrombolysis Date: 2017-05 Impact factor: 2.300
Authors: Oliver Königsbrügge; Silvia Koder; Julia Riedl; Simon Panzer; Ingrid Pabinger; Cihan Ay Journal: Clin Exp Med Date: 2016-04-19 Impact factor: 3.984
Authors: Christian Pfrepper; Michael Metze; Annelie Siegemund; Tristan Klöter; Thomas Siegemund; Sirak Petros Journal: Res Pract Thromb Haemost Date: 2020-04-23